Sopharma Trading ADXBUL:SFT -0.69%82 Current Ratio is 1.25 as of Mar. 2026, which is 14% above its 10-year median of 1.10. GuruFocus rates XBUL:SFT with a GF Score™ of 82/100 and a GF Value™ of €7.65 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 118 Medical Distribution companies, Sopharma Trading AD ranks worse than 63.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sopharma Trading AD's current ratio for the quarter that ended in Mar. 2026 was 1.25.
Sopharma Trading AD has a current ratio of 1.25. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sopharma Trading AD's Current Ratio or its related term are showing as below:
XBUL:SFT'
s Current Ratio Range Over the Past 10 Years
Min: 0.99 Med: 1.1 Max: 1.25
Current: 1.25
During the past 13 years, Sopharma Trading AD's highest Current Ratio was 1.25. The lowest was 0.99. And the median was 1.10.
XBUL:SFT's Current Ratio is ranked worse than 63.56% of 118
companies
in the Medical Distribution industry
Industry Median: 1.395
vs XBUL:SFT: 1.25
Sopharma Trading AD (XBUL:SFT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sopharma Trading AD Current Ratio Related Terms
Sopharma Trading AD Current Ratio Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:SFT vs MCK, CAH, COR: Current Ratio Comparison
For the Medical Distribution subindustry, Sopharma Trading AD's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD Current Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma Trading AD (XBUL:SFT) has a Current Ratio of 1.25 as of Mar. 2026. This is 14% above median its historical median of 1.10. Over the past decade, Sopharma Trading AD's Current Ratio has ranged from 0.99 to 1.25. According to the industry distribution chart, Sopharma Trading AD ranks #75 out of 118 companies in the Medical Distribution industry, placing it in the top 63.6%.
Is Sopharma Trading AD's Current Ratio too high?
Sopharma Trading AD's current Current Ratio of 1.25 is 14% above median its 10-year median of 1.10. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 1.25. The Medical Distribution industry median Current Ratio is 1.40. Sopharma Trading AD's value of 1.25 is 10.4% below this industry median. Based on the distribution chart, Sopharma Trading AD ranks #75 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sopharma Trading AD has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Current Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #75 out of 118 companies for Current Ratio. This places Sopharma Trading AD in the lower half of its industry. The industry median Current Ratio is 1.40. Sopharma Trading AD's value of 1.25 is 10.4% below this benchmark. Historically, Sopharma Trading AD's own Current Ratio has ranged from 0.99 to 1.25 over the past decade. While the company's 10-year median is 1.10 vs. the industry median of 1.40, Sopharma Trading AD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Distribution company?
The median Current Ratio among Medical Distribution companies is 1.40, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current Current Ratio of 1.25 is 10.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Current Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current Current Ratio is 1.25, which is 14% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.65, compared to a current price of €2.86 — trading 62.6% below its estimated fair value. The current Current Ratio is 1.25, which is 14% above median its 10-year median of 1.10 and 10.4% below the Medical Distribution industry median of 1.40. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current Current Ratio is 1.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.86 is trading 62.6% below its estimated GF Value™ of €7.65.
GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.
Key valuation signals for XBUL:SFT:
Current Ratio: 1.25 (14% above median its 10-year median of 1.10)
GF Value™: €7.65 vs. price of €2.86 (62.6% below fair value)
Industry Position: 10.4% below the Medical Distribution median (#75 of 118)
No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score
Get the complete analysis for XBUL:SFT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFT has been successfully added to your 
